Diss. (sammanfattning) Stockholm : Karolinska institutet, 2006. / Härtill 5 uppsatser.

Thesis--University of Oklahoma. / Bibliography: leaves 113-115.

Introduction: In Positron Emission Tomography (PET), the use of resolution modelling (RM) in iterative image reconstruction enables the modelling of aspects of detection which result in mispositioning of measured data and the subsequent blurring of reconstructed images. RM reconstruction can result in significant improvements in spatial resolution, voxel variance and count rate bias and could be a software alternative to detection hardware that is able to achieve higher resolution. Such hardware typically consists of small scintillation crystals, small bore diameters and depth of interaction discrimination, such as for the High Resolution Research Tomograph (HRRT, Siemens), which used a double crystal layer phoswich detector system. However, RM implementation comes with penalties such as slower rates of convergence, potentially higher region of interest variance and Gibbs artefacts. Methods: Assessment of the benefits and drawbacks of RM was done in the first part of this thesis together with the measurement and modelling of spatially varying resolution kernels for different scanner configurations and PET isotopes for the HRRT. It is also unclear as to whether high resolution scanning offers significant advantages over clinical PET-CT scanners for applications in the head. Through direct comparison to our HRRT, we explore whether there are significant advantages of high resolution scanning for an application in the head over clinical PET-CT. For this comparison our Biograph TruePoint TrueV (Siemens) optimised for whole body imaging was used and a novel clinical study using both scanners was set where we scanned Neurofibromatosis 2 (NF2) patients with vestibular schwannomas (VS) using [18F]fluorodeoxyglucose (FDG) and [18F]fluorothymidine (FLT). The clinical objective was to assess if uptake within VS of FLT and FDG could be measured and whether this uptake was predictive of tumour growth. Finally an assessment of the feasibility and impact of reducing the original injected activities in our clinical study was performed using bootstrapping resampling. Conclusions: RM provides greater but additive improvements in image resolution compared to DOI on the HRRT. Isotope specific image based RM could be estimated from published positron range distributions and measurements using fluorine-18. With the clinical project, uptake of FDG and FLT within the VS lesions was observed, these uptake values were correlated to each other, and high uptake was predictive of tumour growth with little differences in predictive power between FLT and FDG. Although there were benefits of the HRRT for imaging small lesions, in our clinical application there was little difference between the two scanners to discriminate lesion growth. Using the PET-CT scanner data and knowledge of lesion location, doses could be reduced to 5-10% without any significant loss of ability to discriminate lesion growth.

A doença de Alzheimer (DA) é uma patologia neurodegenerativa progressiva e a forma de demência mais prevalente no mundo. As alterações fisiopatológicas da DA têm sido associadas a dois marcadores neuropatológicos clássicos: a deposição de placas de β- amilóide e a formação de emaranhados neurofibrilares da proteína tau hiperfosforilada. Porém, devido a complexidade da DA, outros mecanismos têm sido propostos como coadjuvantes no processo neurodegenerativo, entre eles eventos neuroinflamatórios, a quebra da homeostasia de sistemas de neurotransmissão e disfunção sináptica. Esta pletora de eventos patológicos parece preceder a fase de demência por um longo período onde a doença age de forma silenciosa, ou seja, onde não existem evidências sintomatológicas. Na presente tese, avançamos no entendimento de vias de sinalização associadas com a hipersforforilação da proteína tau envolvendo a disfunção da proteína fosfatase 2A e neurotoxicidade do sistema glutamatérgico. Além disso, avaliamos os radiofármacos de tomografia de emissão de pósitrons (PET) disponíveis para visualização in vivo e não invasiva da fisiopatologia da DA. Finalmente, avaliamos um novo biomarcador de PET, o [11C]ABP688, para visualizar flutuações no sistema glutamatérgico e avançamos no entendimento do impacto das células gliais no sinal do PET [18F]FDG, o radiofármaco mais utilizado na clínica atualmente para visualizar metabolismo de glicose cerebral. O [11C]ABP688 pode ser diretamente incluído em estudos clínicos e a reconceptualização do [18F]FDG proposta nesta tese pode alterar a maneira atual como vemos o metabolismo de glicose na DA e em outras doenças neurodegenerativas. Finalmente, nesta tese, avançamos em termos de mecanismos, e no contexto da busca por um diagnóstico precoce e acurado da DA. / Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most prevalent cause of dementia worldwide. The AD pathophysiological features have been associated to two main classic neuropathological markers: depositon of β-amyloid plaques and formation of neurofibrillary tangles of hyperphosphorylated tau. Due to AD complexity, however, additional mechanisms have been proposed as contributors to the neurodegenerative process, such as neuroinflammatory changes, altered neurotransmission, and synaptic dysfunction. These pathological events seem to precede the dementia phase by many years, resulting in a long silent period, i.e., a preclinical phase. In this thesis, we advanced in the understanding of signaling pathways associated with tau hyperphosphorylation, which includes dysfunction of protein phosphatase 2A (PP2A) and glutamatergic neurotoxicity. Furthermore, we underscored radiopharmaceuticals currently available for imaging AD pathophysiology in vivo and non-invasively with positron emission tomography (PET). Finally, we evaluated a new PET biomarker, [11C]ABP688, for visualizing glutamatergic fluctuations and advanced in the understating of how glial cells contribute to the [18F]FDG signal, the widely used radiopharmaceutical in clinical settings for visualizing cerebral glucose metabolism. Our findings have high translational value and direct impact in clinical settings, which can potentially alter the way we interpret glucose metabolism in AD and other neurodegenerative disorders. In summary, in this thesis, we have advanced in terms of molecular mechanisms, and in the use of PET biomarkers toward an early and accurate diagnosis of AD.

A doença de Alzheimer (DA) é uma patologia neurodegenerativa progressiva e a forma de demência mais prevalente no mundo. As alterações fisiopatológicas da DA têm sido associadas a dois marcadores neuropatológicos clássicos: a deposição de placas de β- amilóide e a formação de emaranhados neurofibrilares da proteína tau hiperfosforilada. Porém, devido a complexidade da DA, outros mecanismos têm sido propostos como coadjuvantes no processo neurodegenerativo, entre eles eventos neuroinflamatórios, a quebra da homeostasia de sistemas de neurotransmissão e disfunção sináptica. Esta pletora de eventos patológicos parece preceder a fase de demência por um longo período onde a doença age de forma silenciosa, ou seja, onde não existem evidências sintomatológicas. Na presente tese, avançamos no entendimento de vias de sinalização associadas com a hipersforforilação da proteína tau envolvendo a disfunção da proteína fosfatase 2A e neurotoxicidade do sistema glutamatérgico. Além disso, avaliamos os radiofármacos de tomografia de emissão de pósitrons (PET) disponíveis para visualização in vivo e não invasiva da fisiopatologia da DA. Finalmente, avaliamos um novo biomarcador de PET, o [11C]ABP688, para visualizar flutuações no sistema glutamatérgico e avançamos no entendimento do impacto das células gliais no sinal do PET [18F]FDG, o radiofármaco mais utilizado na clínica atualmente para visualizar metabolismo de glicose cerebral. O [11C]ABP688 pode ser diretamente incluído em estudos clínicos e a reconceptualização do [18F]FDG proposta nesta tese pode alterar a maneira atual como vemos o metabolismo de glicose na DA e em outras doenças neurodegenerativas. Finalmente, nesta tese, avançamos em termos de mecanismos, e no contexto da busca por um diagnóstico precoce e acurado da DA. / Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most prevalent cause of dementia worldwide. The AD pathophysiological features have been associated to two main classic neuropathological markers: depositon of β-amyloid plaques and formation of neurofibrillary tangles of hyperphosphorylated tau. Due to AD complexity, however, additional mechanisms have been proposed as contributors to the neurodegenerative process, such as neuroinflammatory changes, altered neurotransmission, and synaptic dysfunction. These pathological events seem to precede the dementia phase by many years, resulting in a long silent period, i.e., a preclinical phase. In this thesis, we advanced in the understanding of signaling pathways associated with tau hyperphosphorylation, which includes dysfunction of protein phosphatase 2A (PP2A) and glutamatergic neurotoxicity. Furthermore, we underscored radiopharmaceuticals currently available for imaging AD pathophysiology in vivo and non-invasively with positron emission tomography (PET). Finally, we evaluated a new PET biomarker, [11C]ABP688, for visualizing glutamatergic fluctuations and advanced in the understating of how glial cells contribute to the [18F]FDG signal, the widely used radiopharmaceutical in clinical settings for visualizing cerebral glucose metabolism. Our findings have high translational value and direct impact in clinical settings, which can potentially alter the way we interpret glucose metabolism in AD and other neurodegenerative disorders. In summary, in this thesis, we have advanced in terms of molecular mechanisms, and in the use of PET biomarkers toward an early and accurate diagnosis of AD.

Dentre as técnicas diagnósticas por imagem, em Medicina Nuclear, têm-se destacado a Tomografia por Emissão de Pósitrons (PET). O PET fornece imagens funcionais da região ou órgão de interesse, possibilitanto o diagnóstico de várias doenças e, também, um mapeamento da evolução ou regressão das mesmas. Os atuais sistemas PET apresentam blocos de cristais arranjados em geometria circular, mas a busca por novos arranjos, em geometrias diferenciadas, é pertinente, pois pode possibilitar um melhor desempenho destes tomógrafos. O objetivo deste estudo é avaliar o desempenho de um sistema PET constituído por blocos de cristais em arranjo elipsoidal. Para tal estudo, fez-se uso do GATE, ambiente de simulação para tomografia por emissão que apresentou resultados satisfatórios comparados à aparelhos utilizados na rotina clínica. Desta forma, elaborou-se dois sistemas PET, o primeiro com 46 blocos de cristais arranjados em geometria circular, no qual, os detectores opostos foram separados a uma distância de 816,4 mm na direção transaxial. No segundo caso, utilizou-se 36 blocos de cristais, arranjados em geometria elíptica, onde os detectores foram separados a uma distância de 500 mm na direção vertical e 816,4 mm na direção horizontal. Uma vez realizadas as simulações, fez-se os testes de validação para Sensibilidade, Fração de Espalhamento, NEC (Noise Equivalente Count Rate) e Resolução Espacial, para então, avaliar e comparar o desempenho do sistema PET para ambas as geometrias propostas. Estes testes foram feitos de acordo com as especificações da norma NEMA NU 2-2007. Para o teste de sensibilidade, com o phantom localizado no centro do FOV transaxial do tomógrafo, obteve-se um ganho no sistema PET, com geometria elíptica, de 28,7% em relação ao sistema convencional, de geometria circular. Para o phantom deslocado à 10 cm do centro do FOV transaxial, a sensibilidade do sistema PET elíptico foi 26,2% superior em relação ao circular. O tempo de aquisição para cada simulação neste teste foi de 400 s. Para os testes de Fração de Espalhamento e NEC foram realizadas 33 simulações, para cada geometria, variando o tempo de aquisição e a atividade. A fração de espalhamento na geometria elíptica foi de 35,5% e na circular 34,6%. Na geometria circular, a curva NEC atinge o pico máximo em 259,3 kcps a uma concentração de atividade de 34,1 kBq ml-1 , já para geometria elíptica, o pico máximo é atingido em 239,1 kcps a uma concentração de atividade de 24,8 kBq ml-1 . As medidas foram adquiridas em três posições transaxiais (x,y) no centro do FOV e, posteriormente, deslocadas em ¼ do centro do FOV, totalizando 6 medidas para cada geometria. Para cada uma destas 6 medidas, encontrou-se a FWHM (largura a meia altura) e a FWTM (largura a 10% do máximo) nos 3 eixos de coordenadas (x,y,z), assim, para cada geometria proposta obteve-se 18 valores de FWHM e 18 valores de FWTM. A geometria elíptica apresentou melhoras na resolução espacial em FWHM em 4 dos 18 valores de resolução. Já para FWTM, a geometria elíptica apresentou melhora em 8 dos 18 valores de resolução. Em relação a FWHM, onde houve melhora na resolução espacial, teve-se um ganho médio de 18,7%. Já as perdas, em resolução espacial foi em média 43,26%. Para FWTM, a melhora em resolução espacial foi em média 12,09%, mas a perda de resolução, neste caso, foi em média 45,59%. Pode-se concluir que a geometria proposta apresenta algumas vantagens em relação a geometria convencional. Na geometria elíptica há uma redução de 10 blocos de cristais em relação a geometria circular, o que possivelmente gera uma redução no custo de fabricação do tomógrafo. Em relação a sensibilidade, há uma melhora significativa para nova geometria, bem como uma redução da concentração da atividade na qual o tomógrafo alcança seu melhor desempenho, embora ocorra uma ligeira diminuição na taxa de contagens no sistema elíptico. Essa redução na concentração de atividade pode ocasionar uma redução no tempo de exame e utilização de menos material radioativo, reduzindo o risco ao paciente e o custo do exame, bem como possibilitando a realização de um maior número de exames num mesmo intervalo de tempo. A fração de espalhamento do sistema elíptico é ligeiramente maior em relação ao sistema circular. A principal perda do sistema PET elíptico está na resolução espacial, onde não houve melhoras para maior parte das medidas realizadas, necessitando de alguns ajustes que pode se dar, entre outras coisas, no arranjo dos blocos de cristais. Acredita-se que ajustes na angulação dos detectores e na formação das coincidências seja possível melhorias nas resoluções, e NEC. / Among the diagnostic imaging techniques, in Nuclear Medicine, have been prominent in Positron Emission Tomography (PET). PET provides functional images of the region or organ of interest, allowing diagnostic of various diseases and also a mapping of the development or regression of the same. Current PET systems feature blocks arranged in circular geometry crystals, but the search for new arrangements, in different geometries, is relevant because it can provide a better performance of these scanners. The objective of this study is to evaluate the performance of a PET system consisting of blocks of crystals ellipsoidal arrangement. For this study, we used the GATE simulation environment for emission tomography that presented satisfactory results compared to the devices used in the clinical routine. This way we prepared two PET systems, the first one containing 46 blocks of crystals arranged in a circular geometry, where the opposite detectors were separated by a distance of 816.4 mm in the transaxial direction. In the second case, we used 36 blocks of crystals arranged in an elliptical geometry, where the detectors are separated a distance of 500 mm in the vertical direction and 816.4 mm in the horizontal direction. After the simulations were performed, the validation tests for sensitivity, scatter fraction, NEC (Noise Equivalent Count Rate) and Spatial Resolution were made, to finally evaluate and compare the performance of the PET system for both proposed geometries. The tests were made accordingly to specified NEMA NU 2-2007 standard. For the sensitivity test, with the phantom located in the center of FOV transaxial of the tomography, we obtained a gain in PET system with elliptical geometry of 28.7% compared to the conventional system, the circular geometry. For the phantom shifted to 10 cm from the center of the transaxial FOV, the sensitivity of PET elliptical system was 26.2% higher than in the circular. The acquisition time for each simulation in this test was 400 s. For Scatter Fraction test and NEC, were made 33 simulations for each geometry, varying the time of acquisition and activity. The scatter fraction in the elliptical geometry was 35,5% and 34,6% in the circular geometry. In the circular geometry, NEC curve reaches its peak in 259.3 kcps at an activity concentration of 34.1 kBq ml-1, for the elliptical geometry, the maximum peak is reached at 239.1 kcps at an activity concentration of 24.8 kBq ml-1. For the spatial resolution test we used a point source containing 18F with 4 MBq activity and acquisition time of 200 s. The measurements were acquired in three transaxials positions (x,y) in the center of FOV and, shifted in ¼ of the center of the FOV, summarizing 6 measurements for each geometry. For each one of these 6 measurements, we found the FWHM (Full width at half-maximum amplitude) and the FWTM (Full width at tenth-maximum amplitude) in the three axis (x,y,z), in this way, for each proposed geometry, we obtained 18 values of FWHM and 18 values of FWTM. The elliptical geometry showed improvement in the spatial resolution in FWHM in 4 of the 18 resolution values. For the FWTM, the elliptical geometry showed improvement in 8 of 18 resolution values. Regarding the FWHM, where there was an improvement in spatial resolution, we obtained the average gain of 18,7%. For the losses, in spatial resolution was an average of 43,26%. For the FWTM, the improvement in spatial resolution was an average percentage of 12,09%, while the loss of resolution had the average percentage of 45,59%. It can be concluded that the proposed geometry showed some advantages regarding the traditional geometry. In the elliptical geometry there is one reduction of 10 blocks of crystals in relation to the circular geometry, which possibly can cut fabrication costs of the tomography. Regarding to sensibility, there is a significant improvement for the new geometry, as well as one reduction of the activity concentration in which the tomography reaches the best performance, although the occurrence of a slight fall in the counts in the elliptical system. This reduction in the activity concentration can help to reduce the test time and the use less radioactive material, reducing the risk for the patients and the test costs, as well as improving the number of tests in the same period of time. The scattering fraction in the elliptical system is slight higher to the circular system. The major loss in the elliptical PET system is the spatial resolution, where there was not improvement for the great fraction of the obtained measurements, requiring some modifications that can be made, in special, in the crystal blocks arrangement. It is believed that some modifications to the angle of the detectors and in the formation of the coincidences can improve the resolutions and NEC.

Mechanical ventilation in itself can harm the lung and cause ventilator-induced lung injury (VILI), which can induce or aggravate acute respiratory distress syndrome (ARDS). Much debate remains over pivotal concepts regarding the pathophysiology of VILI, especially about the precise contribution, kinetics, and primary role of potential VILI mechanisms. Consequently, it remains largely unknown how best to design a well-timed and full-bodied mechanical ventilation strategy. Little is known also about small airways dysfunction in ARDS. Dynamic positron emission tomography (PET) with [18F]fluoro-2-deoxy-D-glucose (18F-FDG) can be used to image cellular metabolism, which during lung inflammation mainly reflects neutrophil activity, allowing the study of regional lung inflammation in vivo. We studied the regional evolution of inflammation using dynamic PET/CT imaging of 18F-FDG in VILI and during different lung-protective mechanical ventilation strategies. By dynamic CT we investigated also the location and magnitude of peripheral airway closure and alveolar collapse under high and low distending pressures and high and low inspiratory oxygen fraction. Piglets were submitted to an experimental model of early ARDS combining repeated lung lavages and injurious mechanical ventilation. The animals were subsequently studied during sustained VILI, or submitted to distinct approaches of lung-protective mechanical ventilation: the one recommended by the ARDS Network (ARDSNet), or to one defined as open lung approach (OLA). The normally and poorly aerated regions - corresponding to intermediate gravitational zones - were the primary targets of the inflammatory process accompanying early VILI, which may be attributed to the small volume of the aerated lung that receives most of ventilation. The ARDSNet strategy did not attenuate global pulmonary inflammation during 27h and led to a concentration of inflammatory activity in the upper and poorly aerated lung regions. The OLA, in comparison with the ARDSNet approach, resulted in sustained and better gas exchange and lung mechanics. Moreover, the OLA strategy resulted in less global and regional inflammation. Dynamic CT data suggested that a significant amount of airway closure and related reabsorption atelectasis occurs in acute lung injury. Whether potential distal bronchioles injury (“bronchiolotrauma”) is a critical and decisive element in ventilator-associated lung injury is a matter for future studies.

Gemcitabine is a highly potent chemotherapeutic nucleoside agent used in the treatment of several cancers and solid tumors. However, it is therapeutically limitated because of toxicity to normal cells and its rapid intracellular deamination by cytidine deaminase into the inactive uracil derivative. Modification at the 4-(N) position of gemcitabine's exocyclic amine to an -amide functionality is a well reported prodrug strategy which has been that confers a resistance to intracellular deamination while also altering pharmacokinetics of the parent drug. Coupling of gemcitabine to carboxylic acids with varying terminal moieties afforded the 4-N-alkanoylgemcitabines whereas reaction of 4-N-tosylgemcitabine with the corresponding alkyl amines gave the 4-N-alkylgemcitabines. The 4-N-alkanoyl and 4-N-alkyl gemcitabine analogues with a terminal hydroxyl group on the 4-N-alkanoyl or 4-N-alkyl chain were efficiently fluorinated either with diethylaminosulfur trifluoride or under conditions that are compatible with the synthetic protocols for 18F labeling, such as displacement of the corresponding mesylate with KF/Kryptofix 2.2.2. The 4-N-alkanoylgemcitabine analogues displayed potent cytostatic activities against murine and human tumor cell lines with 50% inhibitory concentration (IC50) values in the range of low nM, whereas cytotoxicity of the 4-N-alkylgemcitabine derivatives were in the low to modest µM range. The cytostatic activity of the 4-N-alkanoylgemcitabines was reduced by several orders of magnitude in the 2'-deoxycytidine kinase (dCK)-deficient CEM/dCK- cell line while the 4-N-alkylgemcitabines were only lowered by 2-5 times. None of the 4-N-modified gemcitabines were found to be substrates for cytosolic dCK, however all were found to inhibit DNA synthesis. As such, the 4-N-alkanoyl gemcitabine derivatives likely need to be converted to gemcitabine prior to achieving their significant cytostatic potential, whereas the 4-N-alkylgemcitabines reach their modest activity without "measurable" conversion to gemcitabine. Thus, the 4-N-alkylgemcitabines provide valuable insight on the metabolism of 4-N-modified gemcitabine prodrugs.

No description available.

Introduction and Objectives Calcific aortic valve disease (CAVD) is the most common valvular disease, accounting for 50% of all valve disorders and is the third most common cardiovascular disease following coronary disease and hypertension.[1,2] Currently, there is no pharmacological agent capable of reversing or slowing down the progression of CAVD and treatment of severe cases consists of surgical repair or valve replacement[2]. Hence, there is a crucial need for earlier detection using predictive biomarkers that will allow for preventative intervention as opposed to post-symptomatic disease treatment or management. Namely, one target of particular interest is the expression of matrix metalloproteinases (MMPs) (specifically MMP-1, -2, and -9) which are upregulated in CAVD prior to calcification events and have been previously shown to serve as an attractive molecular imaging target.1–3 The primary objective of this study is to assess the feasibility of detecting biomarkers of CAVD by various in vivo imaging modalities, such as PET and echocardiography. In addition, this study assesses disease progression in various mouse strains to qualify an appropriate CAVD animal model. Methods In vivo and ex vivo imaging of C57Bl/6 and ApoE-/- (n = 8 per strain cohort) mouse models are used to link unique features of matrix remodelling with CAVD progression. At baseline and longitudinal follow-up (4, 8, and 12 months), in vivo hemodynamic impairment is assessed through echocardiography, and calcification and MMP activity are measured using PET with a series of radiotracers: [18F]NaF for calcification, [18F]BR351 for the molecular targets of MMP-2 and -9, and [18F]FMBP with molecular target specificity for MMP-13. Following imaging, aortic valve (AV) tissue is harvested, sectioned, and analyzed for calcification, inflammatory markers, collagen types, and MMP activity in AV leaflets. Tracer autoradiography, immunofluorescence, and in situ zymography are used to confirm in vivo imaging results with improved resolution and quantification in valves. Histological sample preparation, experimentation, and analyses are then repeated in human AV tissue samples for relative comparison of biomarker expression in animal models. Results Echocardiography suggests positive signs of disease progression in experimental animal models. In comparison to WT, ApoE-/- mice show: increased peak velocity (p<0.0001), decreased aortic valve area (p<0.001), and irregular valve dynamics. [18F]NaF PET imaging shows expected bone uptake and low calcium-burden in young and WT animals. [18F]FMBP shows increased uptake in the valve area of diseased models at later timepoints, 1.530 compared to <0.001 %ID/g (p<0.005), in disease vs control animals respectively. Furthermore, confirmation of sought-after biomarkers has also been assessed by analysis of various histological sample preparations including the presence of leaflet calcification, upregulation of MMP-2, -9, and -13, matrix remodelling, lipids, inflammatory markers, and activated MMP expression. Conclusion Findings from this study suggest that molecular imaging techniques using target-specific radiotracers, as well as echocardiography for assessment of hemodynamic impairment, are feasible solutions in predicting disease onset in CAVD specific animal models.